Last updated on May 2019

HEPLISAV-B in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis


Brief description of study

This will be an open-label, single arm study design to evaluate HEPLISAV-B in adults with ESRD who are initiating or undergoing hemodialysis.

Detailed Study Description

Eligible participants will receive single doses of HEPLISAV-B at Weeks 0, 4, 8, and 16 and will be followed through Week 68 or end of study (EOS). The study is designed to evaluate the immunogenicity and safety over a 68-week period.

Clinical Study Identifier: NCT03934736

Find a site near you

Start Over

DaVita Clinical Research or Affiliate

Jeffersonville, IN United States
  Connect »